Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05473364 · ClinicalTrials.gov registry record · Phase 1
Acetazolamide in Persons With Type 1 Diabetes - Dose Finding
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05473364 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 12 participants.
The verdict
NCT05473364, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a dose finding trial where participants will receive escalating doses of acetazolamide, each for a 2-week dosing period followed by a 2-week washout period. The three doses examined will be open-label 62.5mg twice daily, 125mg twice daily, and 250mg twice daily of acetazolamide. A baseline Iohexol GFR (glomerular filtration rate) measurement will be performed prior to the first administration of each acetazolamide dose and then again following each dosing period. Including a screening visit and a follow-up visit, there will be a total of 8 study visits over approximately 16 weeks.
Interventions
- DRUG Acetazolamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05473364
The ClinicalTrials.gov registry entry for NCT05473364 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acetazolamide is the first listed.
NCT05473364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05473364 about?
NCT05473364 is a clinical study titled "Acetazolamide in Persons With Type 1 Diabetes - Dose Finding". This is a dose finding trial where participants will receive escalating doses of acetazolamide, each for a 2-week dosing period followed by a 2-week washout period. The three doses examined will be open-label 62.5mg twice daily, 125mg twice daily, and 250mg twice daily of acetazolamide. A baseline I...
What is the current status of trial NCT05473364?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-03-20. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05473364?
The interventions under investigation include: Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT05473364?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.